RayKnowChina Research Map
Shortlist0

Xuzhou Medical University

徐州医科大学

XuzhouUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.4%Leads under 1 in 100 of China's research papers on NPC

Led 9 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
2
Share of China's trials
0.3%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 332025
ThemesImaging & AIRadiotherapy techniqueImmunotherapy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Xuzhou Medical University5
  2. Affiliated Huai'an Hospital of Xuzhou Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.7%Leads under 1 in 100 of China's research papers on ESCC

Led 19 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
19
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesImmunotherapyRadiotherapyMolecular markers & genomics

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Xuzhou Medical University4
  2. Huai'an Hospital, Xuzhou Medical University Counted in the group total2
  3. First People's Hospital, Xuzhou Medical University Counted in the group total2
  4. Xuzhou Central Hospital2
  5. Affiliated Suqian Hospital of Xuzhou Medical University Counted in the group total1
  6. Affiliated Lianyungang Municipal Oriental Hospital of Xuzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. IL-6 is a prognostic biomarker in patients with advanced esophageal squamous cell carcinoma received with PD-1 inhibitors.2025Frontiers in immunologyFree full text
  2. Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway.2025Molecular cancerFree full text
  3. Esophageal squamous cell carcinoma derived sEV-PDL1 exhausts CD8+T cells to promote immunosuppression.2025Molecular immunology
  4. Saikosaponin D suppresses esophageal squamous cell carcinoma via the PI3K-AKT signaling pathway.2025Naunyn-Schmiedeberg's archives of pharmacology
  5. Molecular Mechanism of WWOX Inhibiting the Development of Esophageal Cancer by Inhibiting Hippo Signaling Pathway.2025Biochemical genetics
Trials on ClinicalTrials.gov6
  1. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  2. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  3. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  4. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  5. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  6. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)CompletedNCT04210115Study sitePhase 3Start 2020-02

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.5%Leads under 1 in 100 of China's research papers on HCC

Led 76 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
76
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 222025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsHepatitis B & cirrhosis

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Xuzhou Medical University33
  2. Affiliated Huai'an Hospital of Xuzhou Medical University Counted in the group total8
  3. Affiliated Lianyungang Hospital of Xuzhou Medical University Counted in the group total4
  4. Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University Counted in the group total2
  5. Affiliated Shuyang Hospital of Xuzhou Medical University Counted in the group total1
  6. Xuzhou Central Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity.2026Cell
  2. System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma.2022Journal for immunotherapy of cancerFree full text
  3. P21-activated kinase 5 potentiates the chemoresistant phenotype of liver cancer.2021Signal transduction and targeted therapyFree full text
  4. Symptom Cluster Trajectories Among Patients With Hepatocellular Carcinoma After Partial Hepatectomy: A Longitudinal Study.2025Journal of clinical nursing
  5. Development and validation of a cross-modality tensor fusion model using multi-modality MRI radiomics features and clinical radiological characteristics for the prediction of microvascular invasion in hepatocellular carc2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Trials on ClinicalTrials.gov5
  1. Study Of B7H3 CAR-T Cells in Treating Advanced Liver CancerRecruitingNCT05323201Lead sponsorPhase 1/Phase 2Start 2022-02
  2. β-alanine in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT07317414Study sitePhase 2Start 2025-12
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  4. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  5. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.6%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 56 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
0
Research papers it led
56
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesPeritoneal spread & advanced diseaseImaging & AIEarly detection & endoscopy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Xuzhou Medical University17
  2. Affiliated Huai'an Hospital of Xuzhou Medical University Counted in the group total7
  3. Xuzhou Central Hospital2
  4. Huai'an Hospital, Xuzhou Medical University Counted in the group total2
  5. Affiliated Suqian Hospital of Xuzhou Medical University Counted in the group total2
  6. Affiliated Lianyungang Hospital of Xuzhou Medical University Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Development and External Validation of a CT-Based Radiomics Nomogram to Predict Perineural Invasion and Survival in Gastric Cancer: A Multi-institutional Study.2025Academic radiology
  2. The association between psychological status and the development of early gastric cancer from atrophic gastritis.2025MedicineFree full text
  3. Radiomics-based assessment of HER2 status and prognosis in gastric cancer: a retrospective dual-center CT study.2025Abdominal radiology (New York)
  4. Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving immunotherapy combined with chemotherapy.2025World journal of gastroenterologyFree full text
  5. Analysis of multiple factors influencing the survival of patients with advanced gastric cancer.2024AgingFree full text
Trials on ClinicalTrials.gov6
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  3. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  4. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  5. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  6. Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric CancerStatus unknownNCT02805829Lead sponsorPhase 1/Phase 2Start 2017-01

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.6%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 13 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.5%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 6 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 3320232024: 1120242025: 002025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
2.7%Leads about 1 in 36 of China's research papers on Myeloma ▲ from 1.5%

Led 46 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
5
Research papers it led
46
Trials it led
6
Share of China's trials
1.2%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025
ThemesCAR-T & cell therapyRelapse & resistanceDiagnosis, MRD & risk

Hospitals counted here

  1. Affiliated Hospital of Xuzhou Medical University37
  2. Affiliated Lianyungang Hospital of Xuzhou Medical University3
  3. Affiliated Tengzhou Hospital of Xuzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyFree full text
  2. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.2022Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  3. The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy.2025Frontiers in immunologyFree full text
  4. Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.2025International urology and nephrology
  5. Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.2025The Lancet. Haematology
Trials on ClinicalTrials.gov6
  1. Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCTNot yet recruitingNCT06963866Lead sponsorPhase 2Start 2025-05
  2. Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple MyelomaNot yet recruitingNCT07034755Lead sponsorN/AStart 2025-07
  3. Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)RecruitingNCT06759181Lead sponsorPhase 1/Phase 2Start 2024-12
  4. Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)RecruitingNCT06196255Lead sponsorPhase 1/Phase 2Start 2023-12
  5. Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple MyelomaRecruitingNCT06132711Lead sponsorPhase 1/Phase 2Start 2023-11
  6. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.9%Leads under 1 in 100 of China's research papers on B-ALL New since 2021

Led 2 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
1
Share of China's trials
0.4%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025
ThemesCAR-T & cell therapyChildrenSide effects (CRS, neurotoxicity)

Hospitals counted here

  1. Affiliated Hospital of Xuzhou Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
1.5%Leads about 1 in 68 of China's research papers on Aplastic anaemia ▲ from 0.4%

Led 6 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
1
Share of China's trials
1.0%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 1120242025: 112025
ThemesImmunosuppressive treatmentChildrenStem cell transplant

Hospitals counted here

  1. Affiliated Hospital of Xuzhou Medical University5
  2. Affiliated Huai'an Hospital of Xuzhou Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.8%Leads under 1 in 100 of China's research papers on HLH New since 2021

Led 3 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
1
Share of China's trials
2.1%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 002025
ThemesChildrenDiagnosis & prognosisEBV & infection triggers

Hospitals counted here

  1. Affiliated Hospital of Xuzhou Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
2.6%Leads about 1 in 38 of China's research papers on Myasthenia gravis ▲ from 1.7%

Led 13 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
1
Research papers it led
13
Trials it led
1
Share of China's trials
1.1%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025
ThemesAntibodies & diagnosisBiologic & complement drugsPregnancy, children, older adults

Hospitals counted here

  1. Affiliated Hospital of Xuzhou Medical University13
  2. People's Hospital, Xuzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
0.8%Leads under 1 in 100 of China's research papers on Anti-NMDA receptor encephalitis New since 2021

Led 2 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Affiliated Suqian Hospital of Xuzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Efgartigimod-rituximab sequential therapy in Anti-NMDAR encephalitis: real-world evidence for a novel salvage-maintenance strategy.2025Journal of neurology
  2. Anti-N-methyl-D-aspartate receptor encephalitis in adults: a systematic review and analysis.2024Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.5%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 5 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Xuzhou Medical University4
  2. Affiliated Huai'an Hospital of Xuzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. 2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide alleviates idiopathic pulmonary fibrosis through activation of LGALS3-mediated AGE-RAGE signaling pathway.2025International immunopharmacology
  2. CSF3 aggravates acute exacerbation of pulmonary fibrosis by disrupting alveolar epithelial barrier integrity.2024International immunopharmacology
  3. Fatty acid metabolism-related genes in bronchoalveolar lavage fluid unveil prognostic and immune infiltration in idiopathic pulmonary fibrosis.2022Frontiers in endocrinology
  4. PEDF is an antifibrosis factor that inhibits the activation of fibroblasts in a bleomycin-induced pulmonary fibrosis rat model.2022Respiratory research
  5. Characterization of the heterogeneity of endothelial cells in bleomycin-induced lung fibrosis using single-cell RNA sequencing.2021Angiogenesis
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  5. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Study sitePhase 2Start 2024-08
  6. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.4%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis

Led 3 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.0%Leads none of China's research papers on IgA nephropathy

Led 0 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
1
Share of China's trials
0.9%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov2
  1. To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA NephropathyActive, not recruitingNCT07098897Lead sponsorPhase 3Start 2024-08
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
1.3%Leads about 1 in 75 of China's research papers on Primary biliary cholangitis New since 2021

Led 4 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Affiliated Huai'an Hospital of Xuzhou Medical University1
  2. Affiliated Changshu Hospital of Xuzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
2.0%Leads about 1 in 50 of China's research papers on Primary sclerosing cholangitis New since 2021

Led 2 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

PubMed searchClinicalTrials.gov